Unlike other international guidelines but in accord with the earlier Japanese Society of Hypertension (JSH) guidelines, the 2019 JSH guidelines ("JSH 2019") continue to emphasize the importance of out-of-office blood pressure (BP) measurements obtained with a home BP device. Another unique characteristic of JSH 2019 is that it sets clinical questions about the management of hypertension that are based on systematic reviews of updated evidence. JSH 2019 states that individuals with office BP < 140/90 mm Hg do not have normal BP. The final decisions regarding the diagnosis and treatment of hypertension should be performed based on out-of-office BP values together with office BP measurements. For hypertensive adults with comorbidities, the office BP goal is usually <130/80 mm Hg and the home BP goal is <125/75 mm Hg. Recommendations of JSH 2019 would be valuable for not only
| INTRODUC TI ON
Hypertension is one the most important risk factors for cardiovascular events worldwide. In Japan, cardiovascular events have had an impact on mortality that is similar to the impact of cancer. Adequate blood pressure (BP) control is thus critical for the prevention of cardiovascular events. The Japanese Society of Hypertension (JSH) first published its guidelines for the management of hypertension in 2000, and the guidelines were revised in 2004 (JSH 2014 , and 2019 (JSH 2019). 1, 2 As one of the unique characteristics is common to the previous JSH guidelines, the JSH 2019 guidelines continue to emphasize the importance of the use of out-of-office BP measurements obtained with a home BP device, unlike other international guidelines. Another unique characteristic of JSH 2019 is that it sets clinical questions regarding the management of hypertension, based on systematic reviews that clarified updated evidence. Several of those systematic reviews are described herein. JSH 2019 also refers to two major international guidelines, that is, the 2017 American College of Cardiology/American Heart Association guidelines (ACC/AHA) and the 2018 European Society of Cardiology/European Society of Hypertension (ESH/ESC) blood pressure guidelines, which were recently revised. 3, 4 Here, we focus on the changes in JSH 2019 compared with JSH 2014 regarding the treatment of hypertension in clinical practice settings and offer perspectives on the management of Asian hypertensive patients.
| DEFINITION OF HYPERTENS ION
In JSH 2014, individuals with office BP values <140/90 mm Hg were regarded as having normal-range BP. However, the term "normalrange" was removed in JSH 2019. In addition, the definitions of optimal BP (<120/80 mm Hg), normal BP (120-129/80-84 mm Hg), and high-normal BP (130-139/85-89 mm Hg) in JSH 2014 were replaced by normal BP, high-normal BP, and elevated BP, respectively, in JSH 2019 (Tables 1 and 2 ).
The authors of a Japanese cohort study reported that the lowest cardiovascular disease (CVD) incidence was in the population with office BP < 120/80 mm Hg, and the population with office systolic blood pressure (SBP) ≥ 140 mm Hg or office diastolic blood pressure (DBP) ≥ 90 mm Hg had a significantly greater risk of CVD compared with the population with office SBP < 120 mm Hg or office DBP < 80 mm Hg. 5, 6 It was also reported that individuals with office BP 120-129/80-84 mm Hg and office BP 130-139/85-89 mm Hg had a significantly higher incidence of CVD compared with those with office BP < 120/80 mm Hg. 7 The use of the term "normal" in the JSH 2014 classification for office BP 120-139/80-89 mm Hg was thus suspected to result in a misunderstanding regarding the management of hypertension. Although the definition of hypertension does not change between JSH 2014 and JSH 2019, JSH 2019 emphasizes that both patients and physicians should be aware of the risk of hypertension at lower BP levels, and they should consider non-pharmacological therapy interventions including lifestyle modification. On the other hand, 2017 ACC/AHA guideline emphasize the diagnosis of hypertension as ≥130/80 mm Hg. 3 For not only Japanese population but also Asian population, earlier diagnosis of hypertension would be important, because stroke events are higher in Asian population than in Western population. 8 In addition, the contribution of increased BP for CVD events is also steeper in Asian population than in Western population. 9
| OUT-OF-OFFI CE B P ME A SUREMENT
The JSH guidelines prior to 2019 emphasized the diagnosis and treatment of hypertension assessed by out-of-office BP measurement | 3
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(especially home BP measurement) as an adjunct to office BP ( Figure 1 ). The recent US blood pressure guidelines also recommend this strategy for the management of hypertension. Several cohort studies revealed that compared with office BP, home BP was more strongly associated with the risk of CVD, [10] [11] [12] [13] but the populations of most of the previous studies were limited to individuals in the general community.
Evidence obtained in studies of clinical populations concerning the association between home BP and CVD risk has emerged more recently. The Home blood pressure measurement with Olmesartan Naïve patients to Establish Standard Target blood pressure (HONEST) study was a prospective observational study of 21 591
Japanese hypertensive patients who were followed for an average of 2.02 years. 14 The results of the HONEST study demonstrated that (a) home BP measurements taken in the morning were positively associated with CVD risk, and (b) the minimum-risk morning home BP level was 124 mm Hg as assessed by a spline regression analysis. In addition, the participants with morning home SBP ≥ 145 mm Hg and office SBP < 130 mm Hg were associated with CVD risk compared with the participants with morning home SBP < 125 mm Hg and office SBP < 130 mm Hg (hazard ratio [HR] 2.47, 95%CI: 1.20-5.08).
The Japan Morning Surge-Home Blood Pressure (J-HOP) study was a nationwide prospective observational study of 4310 Japanese with a history of or risk factors for CVD who were followed for 4 years. 15 The J-HOP results demonstrated that the morning home SBP values obtained during a 14-day period provided superior risk of incident stroke beyond the traditional risk factors (the C statistic value was increased from 0.756 to 0.802) in a model that included conventional CVD risk factors and office SBP. However, this improvement was significantly attenuated by the simultaneous assessment of morning and evening SBP (C statistic, 0.794). Thus, in Japanese hypertensive patients, home BP measurement-especially when performed in the morning-has been recommended for the management of hypertension.
Masked hypertension, which is elevated out-of-office BP despite normal office BP, is an important phenomenon with clinical significance. Since a number of studies have obtained evidence that home BP has stronger prognostic power than office BP, masked hypertension defined based on both home BP and office BP is naturally expected to present a risk of CVD. However, this evidence is not sufficient. In the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study, which was an observational analysis of 2051 residents of a town in Italy who were followed for 12.3 years, only two home BP measurements were performed at baseline. 16 The analysis (in an unadjusted model) revealed that compared with normotension (ie, home BP: <135 mm Hg SBP and <83 mm Hg DBP and office BP < 140/90 mm Hg), masked hypertension (ie, home BP: ≥135 mm Hg SBP or ≥83 mm Hg DBP, plus office BP < 140/90 mm Hg) was associated with a risk of CVD death. However, after adjustment for age and sex, this association disappeared.
The prognostic power of home BP measurement was also investigated in the Finn-Home study, a nationwide observational population study of 2046 participants in Finland. 17 The participants performed ≥14 home BP measurements and were followed for 7.5 years. For the study's definition of masked hypertension (9.2%), the current recommended cut-off BP levels of home BP (135/85 mm Hg) and office BP (140/90 mm Hg) were used. The unadjusted hazard ratio showed that masked hypertension was associated with a risk of cardiovascular events compared with normotension (HR 2.29, 95%CI: 1.42-3.68), but after adjustment for age and sex, this association disappeared (HR 1.39, 95%CI, 0.86-2.25).
In the J-HOP study, 18 we investigated whether masked hypertension defined based on home BP measurements presented a risk of stroke incidence in a Japanese clinical population. The results of our analyses revealed that masked hypertension posed a greater risk of stroke incidence compared with the controlled BP group after adjustment for traditional cardiovascular risk factors including office BP and cardiovascular end-organ damage (ie, urine In JSH 2019, the use of home BP measurement has focused on the diagnosis of masked hypertension as well as JSH 2014.
One concern about the management of masked hypertension is that there has been no investigation of whether interventions
for masked hypertension will help protect against target organ damage or reduce the risk of CVD. To address this concern, we recently performed a retrospective analysis using the combined data of two open-label multicenter randomized control studies:
the Japan Morning Surge-1 (JMS-1) study 19 as well as the 2017 ACC/AHA guidelines, which state that the BP goal for individuals with any comorbidities is <130/80 mm Hg. A major reason for the use of this value is provided by a systematic review included in JSH 2019 that analyzed six randomized control trials according to JSH 2014 and two other previous systematic reviews. 24, 25 The findings demonstrated that the group of patients who achieved the BP control target (ie, 123-137 mm Hg) showed reduced all cause mortality (OR 0.73, 95%CI: 0.61-0.86) and reduced CVD mortality (OR 0.59, 95%CI: 0.45-0.76) compared with the patients who achieved higher target BP control at 135-149.7 mm Hg. However, the rates of composite CVD events and stroke incidence did not differ between these groups. There was also no significant between-group difference in the risk of adverse events (OR 1.02, 95%CI: 0.89-1.17).
| B P CONTROL TARG E T
The optimum home BP for a hypertensive individual has been defined as a value that is 5 mm Hg less than the office BP provided the office BP is already less than 140/90 mm Hg. Although there is insufficient evidence supporting this definition, the HONEST study showed that morning home BP at 124 mm Hg posed the minimum risk for CVD incidence. In addition, a sub-analysis of that study's population using home BP measurement showed that the CVD incidence was incrementally higher from the lowest risk in the group with <125 mm Hg morning home SBP to the groups with 125 to <135, 135 to <145, 145 to <155, and ≥155 mm Hg in the SPRINT high-risk population (ie, the patients with prevalent CVD, CKD, a
Framingham CVD risk score ≥15%, or ≥75 years old) and in SPRINTexcluded high-risk population (patients with diabetes or prevalent stroke). 26 Therefore, 125/75 mm Hg as a target home BP value corresponding to 130/80 mm Hg as the target office BP value would be reasonable. Although the evidence for the benefit of strict BP control is not enough in Asian population, lower BP control would be important in not only Western population but also Asian population.
| B P TARG E T FOR ELDERLY P OPUL ATIONS
The aging of society is currently a global burden in Asian population and worldwide. The Japanese average life expectancy is the highest in the world (84.2 years old). In Japan, approx. 70% of the population with hypertension are elderly (≥75 years old). It is therefore impor- The systematic review mentioned above included the SPRINT study, which largely contributed to the results of the systematic review. 27 In the SPRINT study, intensive BP control (<120 mm Hg SBP) significantly reduced the rate of CVD events compared with standard BP control (<140 mm Hg SBP). A similar result was observed regarding heart failure hospitalizations. In many countries, the incidence and prevalence of heart failure are increasing as a result of the Blood pressure management using out-of-office BP may also be important for patients with HFpEF. We used ambulatory blood pressure monitoring (ABPM) for groups of patients with HFpEF (n = 232) and HFrEF (n = 276), 29 and the results showed that the riser BP pat- Another concern in the management of hypertension in elderly populations is whether intensive treatment worsens cognitive function or dementia, because several papers implicated cerebral hypoperfusion in small vessel disease, which is a major risk factor for dementia. 30 In JSH 2019, a meta-analysis of 10 long-term prospective longitudinal observational studies reported that the risk of developing dementia was low in patients being treated with antihypertensive drugs (RR 0.86, 95%CI: 0.75-0.99). A sub-analysis of the SPRINT study patients showed that intensive treatment did not significantly reduce the risk of probable dementia compared with standard treatment, but it significantly reduced the risk of mild cognitive impairment (HR 0.81, 95%CI: 0.69-0.95). 31 We reported that the riser BP pattern was negatively associated with the brain matter volume assessed by brain magnetic resonance imaging (MRI), which itself was associated with cognitive function in 55 unmedicated elderly hypertensive patients (average age 72.7 years). 32 We also investigated the association between BP variability assessed by However, more recently, a substudy of the SPRINT populations compared the changes in cerebral white matter lesions and brain volume assessed by brain MRI between an intensive-treatment group and a standard-treatment group. 34 In that study, 670 pa- 
| TRE ATMENT WITH ANTIHYPERTENS IVE DRUG S
JSH 2019 recommends that calcium (Ca) channel blockers (CCBs), angiotensin II receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, and diuretics should be selected as the firstline antihypertensive drugs. This recommendation is equivalent to those of JSH 2014. A study of an eastern Asian population reported that monotherapy with a CCB was more effective for BP reduction than other classes of antihypertensive drugs. 35 We surveyed health care practitioners and specialists in Asia and observed that 48% of them preferred a CCB as the best choice of antihypertensive drug for the first-line treatment of Asian hypertensive patients with no complications. 36 JSH 2019 recommends combination therapy with different classes of antihypertensive drugs to achieve the BP control target; for example, an ARB or ACE plus a CCB, or an ARB or ACE plus diuretics, or CCB plus diuretics.
Although it is not yet clear which combination is the best for hypertensive treatment, our previous findings may resolve this issue. The RAS inhibitors tended to reduce the risk of cardiovascular outcomes compared with all of the other hypertensive drugs examined, but the difference was not significant (RR 0.93, 95%CI: 
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